News and views from the world of clinical oncology and hematology.
Oncology Care in the Ongoing COVID-19 Pandemic: Expert Commentary
6:14Recently, Dr. Govind Persad, of the University of Denver Sturm College of Law, wrote an op-ed for The ASCO Post entitled “Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic.”On this episode of the podcast, Dr. Persad further discusses the challenges that patients with cancer and their physicians face surrounding COVID-19, as well as some possible solutions. As hospitals and providers have coped with those in urgent need of care, the question of how to prioritize cancer treatments has come to the fore.To listen to more podcasts from ASCO, visit asco.org/podcasts.
FDA Approvals in Breast and Cervical Cancers
16:08This week, the FDA approved new indications for two drugs. The first approval was for abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who are at high risk of disease recurrence and who also have a Ki67 score of 20% or higher. The next day, the agency approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1.To listen to more podcasts from ASCO, visit asco.org/podcasts.
Lung Cancer Data From the ESMO Congress 2021
10:21This week, we’re hearing about lung cancer data from the ESMO Congress 2021—specifically, a novel tyrosine kinase inhibitor for HER2 exon 20–mutated non–small cell lung cancer, and a second-line vaccine for HLA-A2–positive disease.To listen to more podcasts from ASCO, visit asco.org/podcasts.
ESMO Congress 2021: News in Genitourinary Cancers
15:07This week, we explore more findings presented during the virtual ESMO Congress 2021—specifically, data in genitourinary oncology. We’ll hear from researchers on the efficacy and safety of abiraterone acetate added to different regimens for different types of prostate cancer, as well as patient-reported quality of life with adjuvant pembrolizumab vs placebo for renal cell carcinoma.To listen to more podcasts from ASCO, visit asco.org/podcasts.
High-Impact Research From the ESMO Congress 2021
14:41On September 16th, the virtual ESMO Congress 2021 began. This week, we’ll hear from the authors of three influential, late-breaking studies presented at the meeting.To listen to more podcasts from ASCO, visit asco.org/podcasts.
News From the IASLC 2021 World Conference on Lung Cancer
15:03This week, we’re hearing about three abstracts presented during the IASLC 2021 World Conference on Lung Cancer, focusing on clinical trial enrollment during the COVID-19 pandemic, air pollution's role in lung cancer risk, and strategies for reducing barriers and improving cancer care in low-resource areas.To listen to more podcasts from ASCO, visit asco.org/podcasts.
Withdrawal of Atezolizumab's Indication for Metastatic Triple-Negative Breast Cancer
9:27This week, we’re reviewing the details of Genentech’s decision to withdraw atezolizumab’s indication for metastatic triple-negative breast cancer. We’ll then hear about a systematic review and meta-analysis that provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy.Coverage of stories discussed this week on ascopost.com:Update on U.S. Indication for Atezolizumab in PD-L1–Positive Metastatic Triple-Negative Breast CancerProfile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based TherapyTo listen to more podcasts from ASCO, visit asco.org/podcasts.
Recent FDA Approvals: dMMR Solid Tumors and von Hippel Lindau–Associated Cancers
14:18This week, we’ll be reviewing two recent FDA approvals in the oncology space, for patients with mismatch repair–deficient, or dMMR, recurrent or advanced solid tumors, and for adult patients with cancers associated with von Hippel-Lindau (VHL) disease.Coverage of stories discussed this week on ascopost.com:FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid TumorsFDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau DiseaseTo listen to more podcasts from ASCO, visit asco.org/podcasts.
Breakthrough COVID-19 Infection in Vaccinated Health-Care Workers
11:30This week, we’ll be discussing a study that examined rates of breakthrough COVID-19 infection in vaccinated health-care workers. Then, we’ll move on to a report that compared the efficacy of different durations of anastrozole treatment in patients with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy.Coverage of stories discussed this week on ascopost.com:Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care WorkersOutcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast CancerTo listen to more podcasts from ASCO, visit asco.org/podcasts.
Presentations From the 2021 Pan Pacific Lymphoma Conference
12:16On this episode, we’re hearing from experts presenting data on hematologic malignancies during the 2021 Pan Pacific Lymphoma Conference, which begins on August 9 and concludes on August 13.To listen to more podcasts from ASCO, visit asco.org/podcasts.